Condition
HER2-positive Advanced Solid Tumors
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (2)
Trial Status
Unknown1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05245058Early Phase 1RecruitingPrimary
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
NCT03219268Phase 1Completed
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
NCT05810103Phase 1UnknownPrimary
A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors
Showing all 3 trials